Npwt denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for npwt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Negative Pressure Wound Therapy (NPWT) as Duplicate Therapy

Aetna may deny a claim for Negative Pressure Wound Therapy (NPWT) as "duplicate therapy" when its review indicates that another wound care modality — such as a different wound VAC device, a home-health wound care service, or a separately billed wound therapy protocol — has already been authorized or billed for the same wound during the same treatment period. This is frequently a claims-processing issue or a documentation mismatch rather than a clinical determination that NPWT is inappropriate.

## Why This Denial Is Appealable

Duplicate-therapy denials often rest on a system flag that does not account for the clinical distinction between different wound care approaches. NPWT is a distinct therapeutic modality — it is not clinically interchangeable with passive wound dressings, wound irrigation, or selective debridement. If the prior service billed was clinically different, was performed at a different care site, or addressed a different clinical phase of the wound, the duplicate-therapy finding is factually incorrect and should be reversed.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA §2719, you have the right to a full internal appeal. Request the specific claim or service line that Aetna identified as duplicative.
• External review: After a final internal denial, binding independent external review by an IRO is available under ACA §2719. File within the general four-month external-review window.
• Expedited review: If the wound is acute or deteriorating and delayed access to NPWT poses a health risk, request expedited internal and external review.

## Concrete Appeal Steps and Timeline

1. Request from Aetna the specific claim, service line, and date of service that was identified as duplicating the NPWT claim. 2. Pull the relevant remittance advice and the EOB to identify exactly which procedure codes are in conflict. 3. Have the treating clinician document in writing why the two services are clinically distinct — or, if a billing error occurred, submit a corrected claim alongside the appeal. 4. File the internal appeal with the clinical distinction letter and corrected claim if applicable. 5. Escalate to external review if the internal appeal fails.

## Documentation to Gather

• EOB and remittance records: The specific claims that Aetna flagged as duplicative, with dates of service and procedure codes.
• Clinical distinction letter: A signed letter from the treating clinician explaining that the two services are not clinically identical — different devices, different wound phases, or different care settings.
• Wound care treatment record: A chronological wound-care log showing the distinct roles of each service in the overall treatment plan.
• Medical-necessity documentation for NPWT: Wound type, wound dimensions, treatment-failure history with conventional dressings, and the clinical rationale for NPWT specifically.
• Corrected claim (if applicable): If the duplicate flag arose from a billing error, a corrected claim with the correct codes.

## Criteria-Mapping Structure

Obtain Aetna's published clinical policy bulletin for NPWT. For each coverage criterion, map to chart evidence:

| Aetna Coverage Criterion | Supporting Clinical Evidence | |---|---| | [Copy criterion verbatim from Aetna's NPWT clinical policy bulletin] | [Wound note, measurement, treatment log entry with date] |

Pair this table with a clear explanation of why the flagged "duplicate" service is clinically distinct from NPWT. Together, these form a compelling response to a duplicate-therapy denial.